Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | RXRG | P48443 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440959 | 0.83 | CES2 (0.58) | CES2IDO1ADRB1TSHRALDH1A1 | |
| SCHEMBL9482063 | 0.73 | RXRA (0.54) | CES2IDO1ADRB1TSHRALDH1A1 | |
| SCHEMBL13567133 | 0.73 | CES2 (0.50) | CES2IDO1ADRB1TSHRALDH1A1 | |
| SCHEMBL2095828 | 0.73 | TSHR (0.54) | CES2IDO1TSHRALDH1A1MAPT | |
| SCHEMBL2095830 | 0.73 | TSHR (0.54) | CES2IDO1TSHRALDH1A1MAPT | |
| SCHEMBL8729501 | 0.71 | — | — | |
| SCHEMBL4461544 | 0.71 | CES2 (0.48) | CES2IDO1ADRB1TSHRALDH1A1 | |
| SCHEMBL29121448 | 0.71 | CES2 (0.48) | CES2IDO1ADRB1TSHRALDH1A1 | |
| SCHEMBL2095504 | 0.71 | CES2 (0.48) | CES2IDO1ADRB1TSHRALDH1A1 | |
| SCHEMBL13866628 | 0.71 | RXRA (0.52) | CES2IDO1ADRB1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-1945681-B1 | METHOD FOR PRODUCING ULTRA-HIGH MOLECULAR WEIGHT POLYMERS BY MEANS OF SPECIAL BRIDGED METALLOCENE CATALYSTS | TICONA GMBH (DE) | 2014-12-10 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8034886-B2 | Process for manufacturing high to ultra high molecular weight polymers using novel bridged metallocene catalysts | TICONA GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100056737-A1 | Process for manufacturing high to ultra high molecular weight polymers using novel bridged metallocene catalysts | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2010-03-04 | — | — | US | disclosed |
| US-7598329-B2 | Process for manufacturing ultra high molecular weight polymers using novel bridged metallocene catalysts | TICONA GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1766702-B1 | USE OF POLYMERS FOR UP-CONVERSION AND DEVICES FOR UP-CONVERSION | MERCK PATENT GMBH (DE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1945681-A1 | METHOD FOR PRODUCING ULTRA-HIGH MOLECULAR WEIGHT POLYMERS BY MEANS OF SPECIAL BRIDGED METALLOCENE CATALYSTS | Ticona GmbH (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1766702-A1 | USE OF POLYMERS FOR UP-CONVERSION AND DEVICES FOR UP-CONVERSION | MERCK PATENT GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006008068-A1 | USE OF POLYMERS FOR UP-CONVERSION AND DEVICES FOR UP-CONVERSION | MERCK PATENT GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008127-A1 | METHOD FOR PRODUCING ULTRAHIGH MOLECULAR WEIGHT POLYMERS WHILE USING UNBRIDGED METALLOCENE CATALYSTS | TICONA GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004087316-A1 | TRANSITION METAL CATALYSTS AND USE THEREOF FOR HOMOPOLYMERIZING VINYL ESTERS | CELANESE VENTURES GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004046209-A1 | TRANSITION METAL CATALYSTS FOR PRODUCING POLYVINYL ESTERS | CELANESE VENTURES GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| EP-0609058-B1 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CES2 2243/4885IDO1 2665/4885ADRB1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.